What is already known about this topic?
Cases of thrombosis with thrombocytopenia syndrome and Guillain-Barré syndrome have been reported after receipt of Janssen COVID-19 vaccine.
What is added by this report?
On December 16, 2021, after reviewing updated vaccine effectiveness and safety data, the Advisory Committee on Immunization Practices made a preferential recommendation for the use of mRNA COVID-19 vaccines over the Janssen adenoviral-vectored COVID-19 vaccine in all persons aged ≥18 years in the United States.
What are the implications for public health practice?
Pfizer-BioNTech or Moderna mRNA COVID-19 vaccines are preferred over the Janssen COVID-19 vaccine for primary and booster vaccination. The Janssen COVID-19 vaccine may be considered in some situations, including for persons with a contraindication to receipt of mRNA COVID-19 vaccines.
- Recommendation
- Americas
- United States of America
- Janssen COVID-19 Vaccine
- COVID-19
